Similar articles

• Effect of statins on the progression of bioprosthetic aortic valve degeneration.

  Antonini-Canterin F, Zuppiroli A, Popescu BA, Granata G, Cervesato E, Piazza R, Pavan D, Nicolosi GL. Antonini-Canterin F, et al. Am J Cardiol. 2003 Dec 15;92(12):1479-82. doi: 10.1016/j.amjcard.2003.08.066. Am J Cardiol. 2003. PMID: 14675593
• A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

  Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. Cowell SJ, et al. N Engl J Med. 2005 Jun 9;352(23):2389-97. doi: 10.1056/NEJMoa043876. N Engl J Med. 2005. PMID: 15944423 Clinical Trial.
• Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia.

  Dimitrow PP, Jawień M. Dimitrow PP, et al. Pharmacol Rep. 2010 Nov-Dec;62(6):1250-4. doi: 10.1016/s1734-1140(10)70390-x. Pharmacol Rep. 2010. PMID: 21273686
• Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.

  Malinowski JM. Malinowski JM. Am J Health Syst Pharm. 1998 Nov 1;55(21):2253-67; quiz 2302-3. doi: 10.1093/ajhp/55.21.2253. Am J Health Syst Pharm. 1998. PMID: 9825877 Review.
• [Atorvastatin (Lipitor)].

  Carpentier Y, Ducobu J, Sternon J. Carpentier Y, et al. Rev Med Brux. 1999 Oct;20(5):427-33. Rev Med Brux. 1999. PMID: 10582478 Review. French.